> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Info Collection Revises ANDA Controlled Correspondence
- URL: https://www.fdaweb.com/info-collection-revises-anda-controlled-correspondence/
- Published: 2025-01-13T12:00:00.000Z
- Updated: 2026-09-14T14:50:47.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5158472

*Federal Register* notice: FDA is seeking comments on an information collection revision entitled “Generic Drug User Fee Program.” The revision is related to the agency’s communication program that encourages the submission of sponsor questions at any point in their development and application preparation processes. The collection is being revised to include the submission of “controlled correspondence” within the scope of activity. Controlled correspondence may be submitted by or on behalf of a generic drug manufacturer or related industry prior to submitting an ANDA. To view the notice, click [here](https://public-inspection.federalregister.gov/2025-00564.pdf?ref=fdaweb.com).